All In Biotech

Drug Trial Radar · NCT06091579

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

A Phase 1, Randomized, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Sep 17, 2020

Primary completion

Jan 12, 2021

Study completion Jan 12, 2021

Sponsor

Lead sponsor
Insmed IncorporatedIndustry
Sponsor type
Industry
First posted
Oct 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety and tolerability of single and multiple doses of treprostinil palmitil inhalation powder in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

  • Treprostinil Palmitil Inhalation PowderDrug

    Oral inhalation using a Plastiape capsule-based dry powder inhaler.

  • PlaceboDrug

    Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A and B: Number of Participants who Experienced an Adverse Event (AE)Time frame: Up to Day 31 in Part A and Day 37 in Part B

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • USA001

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.